Published in Science on February 20, 1987
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 6.85
Hydrocarbon hydroxylation by cytochrome P450 enzymes. Chem Rev (2010) 2.34
Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis (2008) 1.95
Unusual cytochrome p450 enzymes and reactions. J Biol Chem (2013) 1.24
Evidence for an ionic intermediate in the transformation of fatty acid hydroperoxide by a catalase-related allene oxide synthase from the Cyanobacterium Acaryochloris marina. J Biol Chem (2009) 1.12
Mechanistic aspects of CYP74 allene oxide synthases and related cytochrome P450 enzymes. Phytochemistry (2009) 1.09
Manganese catalysts for C-H activation: an experimental/theoretical study identifies the stereoelectronic factor that controls the switch between hydroxylation and desaturation pathways. J Am Chem Soc (2010) 1.01
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenet Genomics (2012) 0.92
Rearrangement reactions catalyzed by cytochrome P450s. Arch Biochem Biophys (2010) 0.90
Drug-resistant epilepsia and fulminant valproate liver toxicity. Alpers-Huttenlocher syndrome in two children confirmed post mortem by identification of p.W748S mutation in POLG gene. Med Sci Monit (2011) 0.88
Single mutations change CYP2F3 from a dehydrogenase of 3-methylindole to an oxygenase. Biochemistry (2008) 0.88
Metabolism of capsaicinoids by P450 enzymes: a review of recent findings on reaction mechanisms, bio-activation, and detoxification processes. Drug Metab Rev (2006) 0.86
Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study. Clin Pharmacol Ther (2011) 0.85
Desaturase reactions complicate the use of norcarane as a mechanistic probe. Unraveling the mixture of twenty-plus products formed in enzyme-catalyzed oxidations of norcarane. J Org Chem (2007) 0.82
Acetylene, a mammalian metabolite of 1,1,1-trichloroethane. Biochem J (1992) 0.82
Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions. Curr Neuropharmacol (2009) 0.82
The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid. Br J Clin Pharmacol (1990) 0.79
Case files of the Children's Hospital of Michigan Regional Poison Control Center: the use of carnitine for the management of acute valproic acid toxicity. J Med Toxicol (2007) 0.78
Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy. Pharmaceuticals (Basel) (2010) 0.75
Ab initio dynamics of the cytochrome P450 hydroxylation reaction. J Chem Phys (2015) 0.75
Human cytochrome P450 27C1 catalyzes 3,4-desaturation of retinoids. FEBS Lett (2016) 0.75
Oxidation of C18 Hydroxy-Polyunsaturated Fatty Acids to Epoxide or Ketone by Catalase-Related Hemoproteins Activated with Iodosylbenzene. Lipids (2017) 0.75
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther (2013) 3.29
Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry (1998) 1.93
Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochem Pharmacol (1998) 1.80
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. Br J Clin Pharmacol (1999) 1.66
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol (2001) 1.59
Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys (1996) 1.56
Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics (1997) 1.47
Complete amino acid sequence of the light chain of human blood coagulation factor X: evidence for identification of residue 63 as beta-hydroxyaspartic acid. Biochemistry (1983) 1.47
Membrane-binding domain of the small G protein G25K contains an S-(all-trans-geranylgeranyl)cysteine methyl ester at its carboxyl terminus. Proc Natl Acad Sci U S A (1991) 1.43
Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J Med Chem (1986) 1.42
Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost (2007) 1.41
Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations. Biomed Mass Spectrom (1981) 1.26
Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol (2003) 1.25
Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos (2000) 1.18
Characterization of a urinary bufodienolide Na+,K+-ATPase inhibitor in patients after acute myocardial infarction. Hypertension (1998) 1.17
Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J Biol Chem (2001) 1.15
Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab Dispos (2000) 1.13
Uraemic pruritus and exposure to di(2-ethylhexyl) phthalate (DEHP) in haemodialysis patients. Nephrol Dial Transplant (1996) 1.11
Environmental distribution, analysis, and toxicity of organometal(loid) compounds. Crit Rev Toxicol (2004) 1.08
Uptake of inorganic and organic derivatives of arsenic associated with induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) cells. Toxicol Appl Pharmacol (2004) 1.08
Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos (1996) 1.06
CYP4 isozyme specificity and the relationship between omega-hydroxylation and terminal desaturation of valproic acid. Biochemistry (1995) 1.06
Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem Res Toxicol (1998) 1.05
The analysis of terbutaline in biological fluids by gas chromatography electron impace mass spectrometry. Biomed Mass Spectrom (1979) 1.03
The use of stable isotopes in pharmacological research. Pharmacol Rev (1981) 1.03
A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J Biol Chem (2000) 1.02
Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev (1999) 1.01
Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug Metab Dispos (1999) 1.01
Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding. Biochemistry (1999) 1.01
Biosynthesis of all-trans-retinoic acid from all-trans-retinol: catalysis of all-trans-retinol oxidation by human P-450 cytochromes. Drug Metab Dispos (2000) 1.00
Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther (2012) 1.00
Quantitative determination of the major metabolite of prostaglandins F1alpha and F2alpha in human urine by stable isotope dilution and combined gas chromatography--mass spectrometry. Biochem Med (1976) 0.99
Identification of novel glutathione conjugates of disulfiram and diethyldithiocarbamate in rat bile by liquid chromatography-tandem mass spectrometry. Evidence for metabolic activation of disulfiram in vivo. Chem Res Toxicol (1995) 0.97
Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol (2001) 0.97
In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev (1993) 0.97
Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther (1989) 0.97
Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos (2000) 0.97
The metabolism of clonidine and related imidazoline derivatives in rat liver [proceedings]. Br J Pharmacol (1978) 0.96
Biotransformation of methyl isocyanate in the rat. Evidence for glutathione conjugation as a major pathway of metabolism and implications for isocyanate-mediated toxicities. Chem Res Toxicol (1992) 0.96
Identification of the major covalent adduct formed in vitro and in vivo between acetaminophen and mouse liver proteins. Mol Pharmacol (1985) 0.96
Trichloroethylene oxidative metabolism in plants: the trichloroethanol pathway. Phytochemistry (2001) 0.95
In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4'- and 10-hydroxywarfarin. Drug Metab Dispos (2001) 0.95
Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos (1997) 0.95
Cytochrome P450-dependent desaturation of lauric acid: isoform selectivity and mechanism of formation of 11-dodecenoic acid. Chem Biol Interact (1998) 0.95
Fire eater's risk: lipoid pneumonia following aspiration of a liquid hydrocarbon mixture. Pneumologie (2002) 0.94
The microsomal metabolism and site of covalent binding to protein of 3'-hydroxyacetanilide, a nonhepatotoxic positional isomer of acetaminophen. Drug Metab Dispos (1985) 0.94
Cytochrome P-450-catalyzed desaturation of valproic acid in vitro. Species differences, induction effects, and mechanistic studies. J Biol Chem (1988) 0.94
The covalent binding of acetaminophen to protein. Evidence for cysteine residues as major sites of arylation in vitro. Chem Biol Interact (1984) 0.93
Positional specificity of rabbit CYP4B1 for omega-hydroxylation1 of short-medium chain fatty acids and hydrocarbons. Biochem Biophys Res Commun (1998) 0.93
Wheat bran and soy protein feeding do not alter urinary excretion of the isoflavan equol in premenopausal women. J Nutr (2001) 0.93
Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol (1999) 0.92
Intrinsic isotope effects suggest that the reaction coordinate symmetry for the cytochrome P-450 catalyzed hydroxylation of octane is isozyme independent. J Med Chem (1990) 0.92
Covalent linkage of prosthetic heme to CYP4 family P450 enzymes. Biochemistry (2001) 0.91
Structural characterization of the major covalent adduct formed in vitro between acetaminophen and bovine serum albumin. Chem Biol Interact (1985) 0.91
Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys (1999) 0.91
Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos (1999) 0.90
Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther (1987) 0.90
Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab Dispos (1997) 0.90
Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes. Biochem Pharmacol (2000) 0.90
Purification and characterization of hexahistidine-tagged cyclohexanone monooxygenase expressed in Saccharomyces cerevisiae and Escherichia coli. Protein Expr Purif (2001) 0.90
Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase. Biochem Biophys Res Commun (1995) 0.89
Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab (2001) 0.89
Methylated bismuth, but not bismuth citrate or bismuth glutathione, induces cyto- and genotoxic effects in human cells in vitro. Chem Res Toxicol (2008) 0.88
Selenoxidation by flavin-containing monooxygenases as a novel pathway for beta-elimination of selenocysteine Se-conjugates. Chem Res Toxicol (2001) 0.88
Identification of the lipophilic factor produced by macrophages that stimulates steroidogenesis. Endocrinology (2000) 0.88
Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J (1999) 0.88
Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos (2000) 0.88
Cellular uptake, subcellular distribution and toxicity of arsenic compounds in methylating and non-methylating cells. Environ Res (2009) 0.87
Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol (2001) 0.87
Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B Biomed Sci Appl (1998) 0.87
Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats. Chem Res Toxicol (1997) 0.87
Degradation of rat hepatic cytochrome P-450 heme by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine to irreversibly bound protein adducts. Arch Biochem Biophys (1987) 0.86
Human aromatase in high yield and purity by perfusion chromatography and its characterization by difference spectroscopy and mass spectrometry. Protein Expr Purif (2001) 0.86
Glutathione and N-acetylcysteine conjugates of 2-chloroethyl isocyanate. Identification as metabolites of N,N'-bis(2-chloroethyl)-N-nitrosourea in the rat and inhibitory properties toward glutathione reductase in vitro. Chem Res Toxicol (1993) 0.86
Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry (1998) 0.85
Studies on the metabolism and chiral inversion of ibuprofen in isolated rat hepatocytes. Drug Metab Dispos (1990) 0.85
Pathway of terpene excretion by the appendix of Sauromatum guttatum. Proc Natl Acad Sci U S A (1995) 0.85
Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4. Drug Metab Dispos (2001) 0.85
Studies on the beta-oxidation of valproic acid in rat liver mitochondrial preparations. Drug Metab Dispos (1991) 0.85
Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther (1997) 0.84
Identification of enzymes involved in the metabolism of atrazine, terbuthylazine, ametryne, and terbutryne in human liver microsomes. Chem Res Toxicol (1997) 0.84
Warfarin-amiodarone drug-drug interactions: determination of [I](u)/K(I,u) for amiodarone and its plasma metabolites. Clin Pharmacol Ther (2012) 0.84
Monoacetylhydrazine as a metabolite of isoniazid in man. Clin Pharmacol Ther (1977) 0.84
Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J Pharmacol Exp Ther (1999) 0.84
Baculovirus-mediated expression and purification of human FMO3: catalytic, immunochemical, and structural characterization. Drug Metab Dispos (1997) 0.84
Effects of asbestos on initiation of DNA damage, induction of DNA-strand breaks, P53-expression and apoptosis in primary, SV40-transformed and malignant human mesothelial cells. Mutat Res (2004) 0.84
The use of Brauman's least squares approach for the quantification of deuterated chlorophenols. Biomed Environ Mass Spectrom (1990) 0.84
Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s. Drug Metab Dispos (2001) 0.83
Bioactivation of 4-Ipomeanol by a CYP4B enzyme in bovine lung and inhibition by HET0016. J Vet Pharmacol Ther (2011) 0.83
Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid. Drug Metab Dispos (1986) 0.83
Mass spectrometry. Anal Chem (1992) 0.83
S-oxidative cleavage of farnesylcysteine and farnesylcysteine methyl ester by the flavin-containing monooxygenase. Chem Res Toxicol (1994) 0.82
Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. Chem Biol Interact (1994) 0.82
Occurrence of polychlorinated terphenyls (PCTs) in indoor particulate matter. Environ Health Perspect (1996) 0.82
Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9. Biochemistry (1999) 0.82
Quantitative metabolic profiling of valproic acid in humans using automated gas chromatographic/mass spectrometric techniques. Biomed Environ Mass Spectrom (1989) 0.82